SLC6A19 sirna

SLC6A19 siRNA (Human)

Cat. Num. AAA827639

• Gene Names: SLC6A19; HND; B0AT1
• Reactivity: Human
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: SLC6A19; SLC6A19 siRNA (Human); B0AT1; Sodium-dependent neutral amino acid transporter B(0)AT1; Solute carrier family 6 member 19; System B(0) neutral amino acid transporter AT1; SLC6A19 sirna

• Host: Synthetic
• Reactivity: Human
• Specificity: SLC6A19 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 634

• Applicable Applications for SLC6A19 sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human SLC6A19 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for SLC6A19 sirna

siRNA to inhibit SLC6A19 expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 51468073
• NCBI GeneID: 340024
• NCBI Accession #: NP_001003841.1
• NCBI GenBank Nucleotide #: NM_001003841.2
• UniProt Accession #: Q695T7; A8K446
• Molecular Weight: 71,110 Da
• NCBI Official Full Name: sodium-dependent neutral amino acid transporter B(0)AT1
• NCBI Official Synonym Full Names: solute carrier family 6 (neutral amino acid transporter), member 19
• NCBI Official Symbol: SLC6A19
• NCBI Official Synonym Symbols: HND; B0AT1
• NCBI Protein Information: sodium-dependent neutral amino acid transporter B(0)AT1
• UniProt Protein Name: Sodium-dependent neutral amino acid transporter B(0)AT1
• Protein Family: Sodium-dependent neutral amino acid transporter
• UniProt Gene Name: SLC6A19
• UniProt Synonym Gene Names: B0AT1
• UniProt Entry Name: S6A19_HUMAN

NCBI Description

This gene encodes a system B(0) transmembrane protein that actively transports most neutral amino acids across the apical membrane of epithelial cells. Mutations in this gene result in Hartnup disorder. [provided by RefSeq, Jul 2008]

Uniprot Description

SLC6A19: Transporter that mediates epithelial resorption of neutral amino acids across the apical membrane of epithelial cells in the kidney and intestine. It appears that leucine is the preferred substrate, but all large neutral non-aromatic L-amino acids bind to this transporter. Uptake of leucine is sodium- dependent. In contrast to other members of the neurotransmitter transporter family, does not appear to be chloride-dependent. Defects in SLC6A19 are a cause of Hartnup disorder (HND). HND is an autosomal recessive abnormality of renal and gastrointestinal neutral amino acid transport noted for its clinical variability. First described in 1956, HND is characterized by increases in the urinary and intestinal excretion of neutral amino acids. Individuals with typical Hartnup aminoaciduria may be asymptomatic, some develop a photosensitive pellagra-like rash, attacks of cerebellar ataxia and other neurological or psychiatric features. Although the definition of HND was originally based on clinical and biochemical abnormalities, its marked clinical heterogeneity has led to it being known as a disorder with a consistent pathognomonic neutral hyperaminoaciduria. Defects in SLC6A19 may be a cause of hyperglycinuria (HG). It is a condition characterized by excess of glycine in the urine. In some cases it is associated with renal colic and renal oxalate stones. SLC6A19 deficiency combined with haploinsufficiency of SLC6A20 or partially inactivating mutations in SLC36A2, can be responsible for hyperglycinuria. Defects in SLC6A19 may be a cause of iminoglycinuria (IG). It is a disorder of renal tubular reabsorption of glycine and imino acids (proline and hydroxyproline), marked by excessive levels of all three substances in the urine. SLC6A19 deficiency combined with haploinsufficiency of SLC6A20 or partially inactivating mutations in SLC36A2, can be responsible for iminoglycinuria. Additional polymorphisms and mutations in SLC6A18 can contribute to the IG phenotype in some families. Belongs to the sodium:neurotransmitter symporter (SNF) (TC 2.A.22) family. SLC6A19 subfamily.

Protein type: Transporter; Membrane protein, multi-pass; Membrane protein, integral; Transporter, SLC family

Chromosomal Location of Human Ortholog: 5p15.33

Cellular Component: brush border membrane; integral to plasma membrane; plasma membrane

Molecular Function: neutral amino acid transmembrane transporter activity; neurotransmitter:sodium symporter activity

Biological Process: neutral amino acid transport; neurotransmitter transport; amino acid transport; ion transport; transmembrane transport; response to nutrient

Disease: Iminoglycinuria; Hyperglycinuria; Hartnup Disorder